Cargando…

Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay

Peritoneal dissemination is a major cause of recurrence in patients with malignant tumors in the peritoneal cavity. Effective anticancer agents and treatment protocols are necessary to improve outcomes in these patients. However, previous studies using mouse models of peritoneal dissemination have n...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Ryo, Yokobori, Takehiko, Osone, Katsuya, Tatsuki, Hironori, Takada, Takahiro, Suto, Toshinaga, Yajima, Reina, Kato, Toshihide, Fujii, Takaaki, Tsutsumi, Souichi, Kuwano, Hiroyuki, Asao, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814254/
https://www.ncbi.nlm.nih.gov/pubmed/26716425
http://dx.doi.org/10.1111/cas.12872
_version_ 1782424398746091520
author Takahashi, Ryo
Yokobori, Takehiko
Osone, Katsuya
Tatsuki, Hironori
Takada, Takahiro
Suto, Toshinaga
Yajima, Reina
Kato, Toshihide
Fujii, Takaaki
Tsutsumi, Souichi
Kuwano, Hiroyuki
Asao, Takayuki
author_facet Takahashi, Ryo
Yokobori, Takehiko
Osone, Katsuya
Tatsuki, Hironori
Takada, Takahiro
Suto, Toshinaga
Yajima, Reina
Kato, Toshihide
Fujii, Takaaki
Tsutsumi, Souichi
Kuwano, Hiroyuki
Asao, Takayuki
author_sort Takahashi, Ryo
collection PubMed
description Peritoneal dissemination is a major cause of recurrence in patients with malignant tumors in the peritoneal cavity. Effective anticancer agents and treatment protocols are necessary to improve outcomes in these patients. However, previous studies using mouse models of peritoneal dissemination have not detected any drug effect against peritoneal micrometastasis. Here we used the luciferase assay to evaluate peritoneal micrometastasis in living animals and established an accurate mouse model of early peritoneal microdissemination to evaluate tumorigenesis and drug efficacy. There was a positive correlation between luminescence intensity in in vivo luciferase assay and the extent of tumor dissemination evaluated by ex vivo luciferase assay and mesenteric weight. This model has advantages over previous models because optimal luciferin concentration without cell damage was validated and peritoneal microdissemination could be quantitatively evaluated. Therefore, it is a useful model to validate peritoneal micrometastasis formation and to evaluate drug efficacy without killing mice.
format Online
Article
Text
id pubmed-4814254
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-48142542016-04-11 Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay Takahashi, Ryo Yokobori, Takehiko Osone, Katsuya Tatsuki, Hironori Takada, Takahiro Suto, Toshinaga Yajima, Reina Kato, Toshihide Fujii, Takaaki Tsutsumi, Souichi Kuwano, Hiroyuki Asao, Takayuki Cancer Sci Original Articles Peritoneal dissemination is a major cause of recurrence in patients with malignant tumors in the peritoneal cavity. Effective anticancer agents and treatment protocols are necessary to improve outcomes in these patients. However, previous studies using mouse models of peritoneal dissemination have not detected any drug effect against peritoneal micrometastasis. Here we used the luciferase assay to evaluate peritoneal micrometastasis in living animals and established an accurate mouse model of early peritoneal microdissemination to evaluate tumorigenesis and drug efficacy. There was a positive correlation between luminescence intensity in in vivo luciferase assay and the extent of tumor dissemination evaluated by ex vivo luciferase assay and mesenteric weight. This model has advantages over previous models because optimal luciferin concentration without cell damage was validated and peritoneal microdissemination could be quantitatively evaluated. Therefore, it is a useful model to validate peritoneal micrometastasis formation and to evaluate drug efficacy without killing mice. John Wiley and Sons Inc. 2016-02-09 2016-03 /pmc/articles/PMC4814254/ /pubmed/26716425 http://dx.doi.org/10.1111/cas.12872 Text en © 2015 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Takahashi, Ryo
Yokobori, Takehiko
Osone, Katsuya
Tatsuki, Hironori
Takada, Takahiro
Suto, Toshinaga
Yajima, Reina
Kato, Toshihide
Fujii, Takaaki
Tsutsumi, Souichi
Kuwano, Hiroyuki
Asao, Takayuki
Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay
title Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay
title_full Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay
title_fullStr Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay
title_full_unstemmed Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay
title_short Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay
title_sort establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814254/
https://www.ncbi.nlm.nih.gov/pubmed/26716425
http://dx.doi.org/10.1111/cas.12872
work_keys_str_mv AT takahashiryo establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay
AT yokoboritakehiko establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay
AT osonekatsuya establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay
AT tatsukihironori establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay
AT takadatakahiro establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay
AT sutotoshinaga establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay
AT yajimareina establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay
AT katotoshihide establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay
AT fujiitakaaki establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay
AT tsutsumisouichi establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay
AT kuwanohiroyuki establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay
AT asaotakayuki establishmentofanovelmethodtoevaluateperitonealmicrodisseminationandtherapeuticeffectusingluciferaseassay